Intersect ENT, Inc. (NASDAQ:XENT) headquartered in Menlo Park, will host a conference call for the investment community to discuss the 2Q20 earnings result on 4th August 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.intersectent.com
Earnings Expectation
Intersect ENT, Inc. is expected to report second quarter earnings results, before market open, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.56 per share. Looking ahead, the full year loss are expected at $ 1.73 per share on the revenues of $ 68.37 million.
The Company Outlook
Revenue for 2Q20 are expected in a range of $ 6.67 million ~ $ 8.00 million
Full Year 2020 topline are forecasted in a range of$ 115.00 million ~ $ 119.00 million
Click Here For More Historical Outlooks Of Intersect ENT, Inc.
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.
